Welcome to the fifth and final episode in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In previous episodes, we’ve covered key areas of difference between traditional life science transactions and the new world of digital dealmaking including corporate culture, information governance, defining and valuing the asset, and due diligence. In this final conversation, we pull these strands together and discuss how they influence transaction structure and terms – which both parties must agree on to bring any deal to a successful conclusion. To listen to the final episode, click below. You can also add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
To learn more, follow this link to download a copy of the report that accompanies the podcast series.
